Japanese University Contract Clinical Study Revenues From Drug Makers Continue To Grow
This article was originally published in PharmAsia News
Japan's Ministry of Education, Culture, Sports, Science and Technology released a report August 7 showing that public and private university revenues from drug makers for contract clinical studies continue to grow, increasing 8 percent to ¥17.9 billion last year
You may also be interested in...
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.